Medpace (NASDAQ:MEDP) Releases FY 2025 Earnings Guidance

by · The Cerbat Gem

Medpace (NASDAQ:MEDP – Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 12.260-13.040 for the period, compared to the consensus EPS estimate of 12.480. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Mizuho cut their price target on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a report on Wednesday, April 9th. TD Cowen cut shares of Medpace from a “buy” rating to a “hold” rating and decreased their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partners began coverage on Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price on the stock. Finally, Truist Financial lowered their price target on Medpace from $347.00 to $333.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $357.50.

View Our Latest Stock Report on MEDP

Medpace Stock Down 2.5 %

Shares of NASDAQ MEDP traded down $7.29 during trading on Monday, reaching $288.99. The company had a trading volume of 1,214,658 shares, compared to its average volume of 329,819. Medpace has a 12 month low of $264.72 and a 12 month high of $459.77. The company’s fifty day moving average price is $318.52 and its 200-day moving average price is $333.25. The stock has a market cap of $8.74 billion, a P/E ratio of 22.88, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.05 by $0.62. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts predict that Medpace will post 12.29 earnings per share for the current year.

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Featured Articles